Source: http://www.google.es/patents/USRE42524
Timestamp: 2013-06-20 01:01:06
Document Index: 369094092

Matched Legal Cases: ['Application No. 02729092', 'Application No. 02729092', 'Application No. 2', 'Application No. 2', 'art 1', 'art 1', 'Application No. 2002259107', 'Application No. 2002259107', 'Application No. 2', 'Application No. 2', 'Application No. 05722719', 'Application No. 200580009719', 'Application No. 200580009719']

Patente USRE42524 - Colloidal metal compositions and methods - Google PatentesB�squeda Im�genes Maps Play YouTube Noticias Gmail Drive M�s » B�squeda avanzada de patentes | Historial web | Iniciar sesi�n B�squeda avanzada de patentesPatentesThe present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene...http://www.google.es/patents/USRE42524?utm_source=gb-gplus-sharePatente USRE42524 - Colloidal metal compositions and methods N�mero de publicaci�nUSRE42524 E1Tipo de publicaci�nConcesi�n N�mero de solicitud11/923,344 Fecha de publicaci�n5 Jul 2011 Fecha de presentaci�n24 Oct 2007 Fecha de prioridad30 Abr 2001Tambi�n publicado comoUS7229841, US7387900, US20020192814, US20030053983, US20070160572, US20070231408, US20100143298, US20120134956 N�mero de publicaci�n11923344, 923344, US RE42524 E1, US RE42524E1, US-E1-RE42524, USRE42524 E1, USRE42524E1 InventoresLawrence Tamarkin, Giulio F. Paciotti Cesionario originalCytimmune Sciences, Inc.Citas de patentes (103), Otras citas (138), Citada por (1), Clasificaciones (35) Enlaces externos: USPTO, Cesi�n de USPTO, EspacenetColloidal metal compositions and methodsUS RE42524 E1 Resumen The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.
Citas de patentes Patente citada Fecha de presentaci�n Fecha de publicaci�n Solicitante T�tuloUS27689588 Abr 195430 Oct 1956The B. F. Goodrich CompanyColloidal dispersions of heavy metal compoundsUS278515313 Sep 195412 Mar 1957Crookes-Barnes Laboratories, Inc.Silver proteinUS314514428 Sep 196018 Ago 1964Takeda Pharmacentical Industries, Ltd.Process for manufacturing chromium treated vaccinesUS314903616 Oct 196115 Sep 1964Merck & Co., Inc.Adjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agentUS32699128 Abr 196330 Ago 1966C. F. Boehringer & Soehne Gesellschaft Mit Beschrankter HaftungAluminum oxide depot vaccinesUS339926312 Abr 196527 Ago 1968American Cyanamid CompanyStable adjuvant emulsion compositions comprising the hydrated reaction products of a methallic cation and a fatty acidUS353156525 Sep 196929 Sep 1970American Cyanamid Co.Stable adjuvant emulsion compositions comprising hydrated salts of a polyvalent metallic cation and a higher fatty acidUS35775237 Mar 19694 May 1971Miles Laboratories Inc.Water-insoluble antigenic substances and method of preparing the same and antigenic depot agents incorporating such substancesUS365121116 Oct 196721 Mar 1972Lockheed Aircraft Corp.Virus inactivationUS381982018 Sep 196925 Jun 1974R Us AluisyIrradiated substance and compound and method of preparing the sameUS391941329 Nov 197411 Nov 1975The Board Of Regents Of The University Of NebraskaVaccine for neonatal calf diarrheaUS398322819 Nov 197428 Sep 1976Merck & Co., Inc.Water-in-oil adjuvant compositionUS401625211 Dic 19755 Abr 1977Institut PasteurCalcium phosphate gel for adsorbing vaccinesUS405358710 Ene 197511 Oct 1977Research CorporationMethod of treating viral infectionsUS40693137 Abr 197617 Ene 1978Merck & Co., Inc.Water-in-oil adjuvant compositionUS417726327 Dic 19764 Dic 1979Research CorporationAnti-animal tumor methodUS41961855 Jun 19781 Abr 1980Hoffmann-La Roche Inc.Immunoassay for phencyclidineUS419723712 Feb 19758 Abr 1980Syva CompanyAntibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereofUS419728627 Sep 19778 Abr 1980Southwest Research InstituteTestosterone derivatives and assay methodUS42139647 Dic 197822 Jul 1980Miles Laboratories, Inc.Diphenylhydantoin antibodiesUS421503615 Ago 197829 Jul 1980Research CorporationModified grass pollen antigensUS421843626 Abr 197919 Ago 1980The Upjohn CompanyCompounds and methodsUS432928121 Dic 197911 May 1982Hoffmann-La Roche Inc.Hapten compositionsUS433053022 Dic 198018 May 1982The Procter & Gamble CompanyAnti-arthritic compositions and method using gold salts and organophosphonatesUS433278723 Jun 19801 Jun 1982The Massachusetts General HospitalAssay for beta-adrenergic antagonists and antibody thereforUS433943726 Jul 197913 Jul 1982Research CorporationAnti-tumor methodUS434607416 Ago 197924 Ago 1982National Research Development Corp.Pasteurellosis vaccinesUS445157026 Mar 198129 May 1984The Regents Of The University Of CaliforniaImmunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell lineUS44877805 Feb 198211 Dic 1984Scheinberg; Israel H.Method of treatment of rheumatoid arthritisUS457827022 Feb 198425 Mar 1986Human Oltoanyagtermelo Es Kutato IntezetProcess for the preparation of lyophilized, adsorbed polyvalent vaccinesUS459432526 Mar 198110 Jun 1986The Regents Of The University Of Calif.High fusion frequency fusible lymphoblastoid cell lineUS460825227 Sep 198526 Ago 1986Syntex (U.S.A.) Inc.Chloramphenicol derivatives antigens and antibodiesUS462492126 Abr 198425 Nov 1986Cetus CorporationHuman lymphoblastold cell line and hybridomas derived therefromUS462492324 Ene 198625 Nov 1986Yeda Research And Development Company LimitedMetal-coated polyaldehyde microspheresUS463933614 Jun 198427 Ene 1987Roussel UclafNovel radioactive estradienes labelled with iodineUS46577633 Sep 198514 Abr 1987Michael EbertCombined chrysotherapeutic agents for autoimmune diseasesUS469397520 Nov 198415 Sep 1987The Wistar InstituteHuman hybridroma fusion partner for production of human monoclonal antibodiesUS47103788 Mar 19851 Dic 1987Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteLyophilized hepatitis B vaccineUS472045914 Feb 198519 Ene 1988Medical College Of Wisconsin Research Foundation, Inc.Myelomas for producing human/human hybridomasUS474058911 Jul 198626 Abr 1988Burroughs Wellcome Co.Capsular polysaccharide metal complex vaccinesUS474476014 Ene 198517 May 1988University Of British ColumbiaColloidal sized metal-polysaccharide particlesUS47538733 Feb 198628 Jun 1988Cambridge Bioscience CorporationPeptides for the diagnosis of HTLV-III antibodies, their preparation and useUS481255618 May 198714 Mar 1989VirovahlSynthetic peptide antigen for the detection of HIV-2 infectionUS48807509 Jul 198714 Nov 1989Miragen, Inc.Individual-specific antibody identification methodsUS488242330 Mar 198721 Nov 1989Calpis Food IndustrySubstance-conjugated complement component C1qUS490656413 Mar 19876 Mar 1990The United States Of America As Represented By The Secretary Of The ArmyAntigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigensUS49772869 Sep 198811 Dic 1990Trustees Of The University Of PennsylvaniaGlycolipidsUS501768713 Jun 198821 May 1991Virovahl, S.A.Peptides for the detection of HTLV-1 infectionUS50194975 Jul 198828 May 1991Olsson; LennartHuman squamous lung carcinoma cell specific antigens and antibodiesUS503599522 May 198930 Jul 1991Calpis Food Industry Co., Ltd.Test method involving substance-conjugated complement component C1qUS508942423 Oct 198918 Feb 1992Abbott LaboratoriesMethod and apparatus for heterogeneous chemiluminescence assayUS511260629 Sep 198912 May 1992Kiyama; HiroshiMethod of producing antibodies using colloidal metal as carrierUS512625325 Sep 198630 Jun 1992Suntory LimitedCell lines for use in the preparation of hybridoma cellsUS516975431 Oct 19908 Dic 1992Coulter CorporationBiodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making sameUS521380415 Ene 199125 May 1993Liposome Technology, Inc.Solid tumor treatment method and compositionUS52428289 Nov 19897 Sep 1993Pharmacia Biosensor AbSensing surfaces capable of selective biomolecular interactions, to be used in biosensor systemsUS524877229 Ene 199228 Sep 1993Coulter CorporationFormation of colloidal metal dispersions using aminodextrans as reductants and protective agentsUS526422122 May 199223 Nov 1993Mitsubishi Kasei CorporationDrug-containing protein-bonded liposomeUS52943695 Dic 199015 Mar 1994Akzo N.V.Ligand gold bondingUS537655611 Sep 199227 Dic 1994Abbott LaboratoriesSurface-enhanced Raman spectroscopy immunoassayUS538407321 Ene 199424 Ene 1995Akzo N.V.Ligand gold bondingUS543408824 May 199418 Jul 1995Tosoh CorporationMethod of and kit for energy transfer immunoassay with colloidal particlesUS543616122 Jul 199425 Jul 1995Pharmacia Biosensor AbMatrix coating for sensing surfaces capable of selective biomolecular interactions, to be used in biosensor systemsUS544609012 Nov 199329 Ago 1995Shearwater Polymers, Inc.Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and moleculesUS546660929 Oct 199214 Nov 1995Coulter CorporationBiodegradable gelatin-aminodextran particle coatings of and processes for making sameUS549842122 Feb 199412 Mar 1996Vivorx Pharmaceuticals, Inc.Composition useful for in vivo delivery of biologics and methods employing sameUS552128929 Jul 199428 May 1996Nanoprobes, Inc.Small organometallic probesUS563972526 Abr 199417 Jun 1997Children'S Hospital Medical Center Corp.Angiostatin proteinUS56865785 Ago 199411 Nov 1997Immunomedics, Inc.Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotypeUS57364107 Jun 19957 Abr 1998Sri InternationalUp-converting reporters for biological and other assays using laser excitation techniquesUS587422622 May 199523 Feb 1999H. Lee BrowneIn situ immunodetection of antigensUS592192712 Nov 199713 Jul 1999Axialtome Australia Pty. Ltd.Positioning method and apparatus for X-ray tomographyUS59727205 Jun 199726 Oct 1999Roche Diagnostics GmbhStabilization of metal conjugatesUS623509328 Jun 199922 May 2001Daiwa Fine Chemicals Co., Ltd.Aqueous solutions for obtaining noble metals by chemical reductive depositionUS6274552 *10 Nov 199714 Ago 2001Cytimmune Sciences, Inc.Composition and method for delivery of biologically-active factorsUS640721810 Nov 199818 Jun 2002Cytimmune Sciences, Inc.Method and compositions for enhancing immune response and for the production of in vitro mabsUS64477653 Mar 199910 Sep 2002University Of Southern CaliforniaUse of cytokines and mitogens to inhibit graft versus host diseaseUS652805122 Ago 20014 Mar 2003Cytimmune Sciences, Inc.Methods and compositions for enhancing immune responseUS6528485 *5 Jun 20004 Mar 2003Applied Research Systems Ars Holding N.V.Site-specific preparation of polyethylene glycol-grf conjugatesUS65309448 Feb 200111 Mar 2003Rice UniversityOptically-active nanoparticles for use in therapeutic and diagnostic methodsUS654161727 Oct 19991 Abr 2003Clinical Micro Sensors, Inc.Detection of target analytes using particles and electrodesUS662488613 May 200223 Sep 2003Surromed, Inc.SERS substrates formed by hydroxylamine seeding of colloidal metal nanoparticle monolayersUS666005822 Ago 20009 Dic 2003Nanopros, Inc.Preparation of silver and silver alloyed nanoparticles in surfactant solutionsUS686993220 Nov 200222 Mar 2005Applied Research Systems Ars Holding N.V.Site-specific preparation of polyethlene glycol-GRF conjugatesUS72298418 Mar 200212 Jun 2007Cytimmune Sciences, Inc.Colloidal metal compositions and methodsUS200100555819 Mar 200127 Dic 2001Lawrence TamarkinComposition and method for delivery of biologically-active factorsUS200201035178 Feb 20011 Ago 2002Halas Nancy J.Optically-active nanoparticles for use in therapeutic and diagnostic methodsUS200201928148 Mar 200219 Dic 2002Lawrence TamarkinColloidal metal compositions and methodsUS2003005398330 Abr 200220 Mar 2003Lawrence TamarkinColloidal metal compositions and methodsUS2003018025219 Dic 200225 Sep 2003Lawrence TamarkinMethods and compositions for enhancing immune response and for the production of in vitro MabsUS20040018203 *8 Jun 200129 Ene 2004Kreitman Robert J.Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugatesUS2004002979420 Nov 200212 Feb 2004Applied Research Systems Ars Holding N.V.Site-specific preparation of polyethlene glycol-GRF conjugatesUS2004018000226 Mar 200416 Sep 2004Young David S. F.Cancerous disease modifying antibodiesUS2004021376026 Sep 200328 Oct 2004Paciotti Giulio F.Composition and method for delivery of biologically-active factorsUS2005000343121 Jul 20046 Ene 2005Wucherpfennig Kai W.Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses thereforAU757857B2 T�tulo no disponibleAU760035B2 T�tulo no disponibleAU2003204353B2 T�tulo no disponibleCA2158475A118 Mar 199429 Sep 1994Cytimmune Sciences, Inc.Composition and method for reducing toxicity of biologically-active factorsEP0044722A116 Jul 198127 Ene 1982The Board Of Trustees Of The Leland Stanford Junior UniversityHuman hybridomas, precursors and productsEP0156242A212 Mar 19852 Oct 1985Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteLyophilized hepatitis B vaccineEP0179483A225 Oct 198530 Abr 1986Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteMethod for preparing monoclonal antibodies to HBsAgWO1999024077A2 *10 Nov 199820 May 1999Cytimmune Sciences, Inc.Compositions and methods for targeted delivery of biologically-active factors* Citada por examinadorOtras citasReferencia1Author: Balkwill et al., Title: The Cytokine Network, Publ: Immunology Today, vol./Iss: 10(9), pp. 299-304, Date: Jan. 1, 1989.2Author: Brust et al., Title: Novel Gold-Dithiol Nano-Networks with Non-Metalhe Electronic Properties, Publ: Advanced Materials, vol./Iss: 7(9), pp. 795-797, Date: Jan. 1, 1995.3Author: Calabrese et al., Title: Chemotherapy of Neoplastic Diseases, Publ: Goodman & Gilman's The Pharmacological Basis of Therapeutics, vol./Iss: 9th Edition, pp. 1260-1261, Date: Jan. 1, 1996.4Author: Carter et al., Title: Appendix C, Publ: Chemotherapy of Cancer, vol./Iss: 2nd Ed., pp. 361-367, Date: Jan. 1, 1981.5Author: Ciesiolka et al., Title: An 8- to 10-fold Enhancement in Sensitivity for Quanitation of Proteins by Modified Application of Colloidal Gold (Abstract Only-Applicants do not have complete copy), Publ: Analytical Biochemistry, vol./Iss: 168 (2), pp. 280-283, Date: Feb. 1, 1988.6Author: Ciesiolka et al., Title: An 8- to 10-fold Enhancement in Sensitivity for Quanitation of Proteins by Modified Application of Colloidal Gold (Abstract Only�Applicants do not have complete copy), Publ: Analytical Biochemistry, vol./Iss: 168 (2), pp. 280-283, Date: Feb. 1, 1988.7Author: Cohen, I., Title: Optimization of Dose-Time Factors for a Tumor and Multiple Associated Normal Tissues, Publ: International Journal of Radiation Oncology, vol./Iss: 13, pp. 251-258, Date: Jan. 1, 1987.8Author: Coulombe et al., Title: Cytochemical Demonstrations of Increased Phospholipid Content in Cell Membranes in Chlorphentermine-Induced Phospholipidosis, Publ: Journal of Histochemistry and Cytochemistry, vol./Iss: 37(2), pp. 139-147, Date: Jan. 1, 1989.9Author: De Roe et al., Title: A Model of Protein-Colloidal Gold Interactions, Publ: The Journal of Histochemistry and Cytochemistry, vol./Iss: 35(11), pp. 1191-1198, Date: Jan. 1, 1987.10Author: De Roe et al., Title: A Model of Protein�Colloidal Gold Interactions, Publ: The Journal of Histochemistry and Cytochemistry, vol./Iss: 35(11), pp. 1191-1198, Date: Jan. 1, 1987.11Author: Debrabander et al., Title: Probing Microtobule-Dependent Intracellular Motility with Nanometre Particle Video Ultramicroscopy (nanovid ultramicroscopy) (Abstract Only-Applicants do not have complete copy), Publ: Cytobio, vol./Iss: 43, pp. 273-283, Date: Jan. 1, 1985.12Author: Debrabander et al., Title: Probing Microtobule-Dependent Intracellular Motility with Nanometre Particle Video Ultramicroscopy (nanovid ultramicroscopy) (Abstract Only�Applicants do not have complete copy), Publ: Cytobio, vol./Iss: 43, pp. 273-283, Date: Jan. 1, 1985.13Author: Deng et al., Title: Self-Assembled Monolayers of Alkanethiolates Presenting Tri(propylene sulfoxide) Groups Resist the Adsorption of Protein, Publ: Journal of the American Chemical Society, vol./Iss: 118(19), pp. 5136-5137, Date: May 15, 1996.14Author: Dominguez et al., Title: Effect of Heat Treatment on the Antigen-Binding of Anti-Peroxidase Immunoglobulins in Bovine Colstrum, Publ: Journal of Dairy Science, vol./Iss: 80(12), pp. 3182-3187, Date: Dec. 1, 1998.15Author: Eck et al., Title: Chapter 5: Gene-Based Therapy, Publ: Goodman & Gilman's The Pharmacological Basis of Therapeutics, vol./Iss:, pp. 77-101, Date: Jan. 1, 1996.16Author: Elliott et al., Title: Analysis of Colloidal Gold Probes by Isoelectric Focusing in Agarose Gels (Abstract Only-Applicants do not have complete copy), Publ: Analytical Biochemisty, vol./Iss: 186(1), pp. 53-59, Date: Apr. 1, 1990.17Author: Elliott et al., Title: Analysis of Colloidal Gold Probes by Isoelectric Focusing in Agarose Gels (Abstract Only�Applicants do not have complete copy), Publ: Analytical Biochemisty, vol./Iss: 186(1), pp. 53-59, Date: Apr. 1, 1990.18Author: EPO Searching Authority, Title: Search Report EPO-Application No. 02729092.3, Publ: EPO Search Report, vol./Iss:, pp. 1-6, Date: Jul. 13, 2009.19Author: EPO Searching Authority, Title: Search Report EPO�Application No. 02729092.3, Publ: EPO Search Report, vol./Iss:, pp. 1-6, Date: Jul. 13, 2009.20Author: Fraker et al., Title: Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity, Publ: The Journal of Experimental Medicine, vol./Iss: 170, pp. 1015-1020, Date: Jan. 1, 1989.21Author: Fujimoto, D.-CA Office Action, Title: Canadian Office Action cited in CA Application No. 2,448,607, Publ: Canadian Office Action, vol./Iss:, pp. 1-2, Date: Oct. 12, 2010.22Author: Fujimoto, D.�CA Office Action, Title: Canadian Office Action cited in CA Application No. 2,448,607, Publ: Canadian Office Action, vol./Iss:, pp. 1-2, Date: Oct. 12, 2010.23Author: Goldstein et al., Title: Cardiovascular Effects of Platelet-Activating Factor, Publ: Lipids, vol./Iss: 26(212), pp. 1250-1256, Date: Jan. 1, 1991.24Author: Grainger et al., Title: Polymeric Monolayers on Solid Substrates by Spontaneous Adsorption from Solution, Publ: American Chemical Society-Abstracts of Papers, vol./Iss: Part 1, Pages: Paragraph 074, Date: Aug. 20, 1995.25Author: Grainger et al., Title: Polymeric Monolayers on Solid Substrates by Spontaneous Adsorption from Solution, Publ: American Chemical Society�Abstracts of Papers, vol./Iss: Part 1, Pages: Paragraph 074, Date: Aug. 20, 1995.26Author: Gref et al., Title: The Controlled Intravenous Delivery of Drugs using PEG-Coated Sterically Stabilized Nanospheres, Publ: Advanced Drug Delivery Reviews, vol./Iss: 16, pp. 215-233, Date: Jan. 1, 1995.27Author: Gura, T., Title: Systems for Identifying New Drug are Often Faulty, Publ: Science, vol./Iss: 278, pp. 1041-1042, Date: Nov. 7, 1997.28Author: Hashimoto et al., Title: Action Site of Circulating Interleukin-1 on the Rabbit Brain, Publ: Brain Research, vol./Iss: 540, pp. 217-223, Date: Jan. 1, 1991.29Author: Hisamatsu et al., Title: Platelet Activating Factor Induced Respiratory Mucosal Damage, Publ: Lipds, vol./Iss: 26(12), pp. 1287-1291, Date: Jan. 1, 1991.30Author: Hopkins et al., Title: Early Events Following the Binding of Epidermal Growth Factor to Surface Receptors on Ovarian Granulosa Cells, Publ: European Journal of Cell Biology, vol./Iss: 24, pp. 259-264, Date: Jan. 1, 1981.31Author: IBM TDB et al., Title: Molecular Glue for Highly Controlled Attachment of Macromolecules to Metals, Publ: IBM Technical Bulletin, vol./Iss: 39(09), pp. 1-5, Date: Sep. 1, 1996.32Author: Illum et al., Title: Development of Systems for Targeting the Regional Lymph Nodes for Diagnostic Imaging: In Vivo Behavior of Colloidal PEG-Coated Magnetic Nanospheres in the Rat Following Intestinal Administration, Publ: Pharmaceutical Research, vol./Iss: 18(5), pp. 640-645, Date: Jan. 1, 2001.33Author: Japanese Patent Office, Title: Japanese Patent Application 2000-520153 Office Action as translated by Foreign Associate, Publ: Japanese Office Action, vol./Iss:, pp. 1-10, Date: Oct. 6, 2009.34Author: Japanese Publication, Title: Japanese Laid-Open Publication No. 9-107980 English Abstract only-of Japanese Patent Application 08-231415, Publ:, vol./Iss:, pp. 1-3, Date: Apr. 28, 1997.35Author: Japanese Publication, Title: Japanese Laid-Open Publication No. 9-107980 English Abstract only�of Japanese Patent Application 08-231415, Publ:, vol./Iss:, pp. 1-3, Date: Apr. 28, 1997.36Author: Kang et al., Title: Ultrastructural and Immunocytochemical Study of the Uptake and Distribution of Bacterial Lipopolysaccharide in Human Monocytes, Publ: Journal of Leukemia Biology, vol./Iss: 48, pp. 316-332, Date: Jan. 1, 1990.37Author: Kirchner et al., Title: The Development of Neutralizing Antibodies in a Patient Receiving Subcutaneous Recombinant and Natural Interleukin-2, Publ: Cancer, vol./Iss: 67(7), pp. 1862-1864, Date: Apr. 1, 1991.38Author: Klotz et a., Title: Macromolecule-Small Molecule Interactions: Strong Binding by Intramolecularly Cross-Linked Polylysine, Publ: Biochemistry, vol./Iss: 10(6), pp. 923-926, Date: Jan. 1, 1971.39Author: Koning, et al., Title: Selective Transfer of a Lipophilic Prodrug of 5-Fluorodeoxyuridine from Immunoliposomes to Colon Cancer Cells, Publ: Biochimica et Biphysica Acta, vol./Iss: 1420, pp. 153-167, Date: Jun. 2, 1999.40Author: Krontiris, T.G., Title: Chapter 71: Molecular and Cellular Biology of Cancer, Publ: Internal Medicine, vol./Iss: 4th Ed., pp. 699-729, Date: Jan. 1, 1994.41Author: Lang et al., Title: A New Class of Thiolipids for the Attachment of Lipid Bilayers on Gold Surfaces, Publ: Langmuit, vol./Iss: 10(1), pp. 197-210, Date: Jan. 1, 1994.42Author: Lanzavecchia, Title: Identifying Strategies for Immune Interveator, Publ: Science, vol./Iss: 260, pp. 937-944, Date: Jan. 1, 1993.43Author: Lemmon et al., Title: Preparation and Characterization of Nanocomposites of Poly(ethylene oxide) with Layered Solids, Publ:, vol./Iss:, pp. 43-54, Date: Jan. 1, 1995.44Author: Leuvering et al., Title: A Sol Particle Agglutination Assay for Human Chorionic Gonadotrophin (Abstract Only-Applicants do not have complete copy), Publ: Journal of Immunological Methods, vol./Iss: 45(2), pp. 183-194, Date: Jan. 1, 1981.45Author: Leuvering et al., Title: A Sol Particle Agglutination Assay for Human Chorionic Gonadotrophin (Abstract Only�Applicants do not have complete copy), Publ: Journal of Immunological Methods, vol./Iss: 45(2), pp. 183-194, Date: Jan. 1, 1981.46Author: Lezzi et al., Title: Chelating Resins Supporting Dithiocarbamate and Methylthiourea Groups in Adsorption of Heavy Metal Ions, Publ: Journal of Applied Polymer Science, vol./Iss: 54(7), pp. 889-897, Date: Nov. 14, 1994.47Author: Lezzi et al., Title: Synthesis of Thiol Chelating Resins and Their Adsorption Properties toward Heavy Metal Ions, Publ: Journal of Polymer Science, vol./Iss: 32, pp. 1877-1883, Date: Jan. 1, 1994.48Author: Li et al., Title: Plasma Protein Interactions with Copolymer-Stabilized Colloids, Publ: Dissertation Abstracts International, vol./Iss: 54(7), pp. 3735-B, Date: Jan. 1, 1994.49Author: Magez et al., Title: Specific Uptake Tumor Necrosis Factor-a is Involved in Growth Control of Trypanosoma brucei, Publ: The Journal of Cell Biology, vol./Iss: 137(3), pp. 715-727, Date: May 5, 1997.50Author: Magez et al., Title: Specific Uptake Tumor Necrosis Factor�a is Involved in Growth Control of Trypanosoma brucei, Publ: The Journal of Cell Biology, vol./Iss: 137(3), pp. 715-727, Date: May 5, 1997.51Author: Marshall, E., Title: Gene Therapy's Growing Pains, Publ: Science, vol./Iss: 269(5227), pp. 1050-1055, Date: Aug. 25, 1995.52Author: Maruyama et al., Title: Targeting Efficiency of PEG-Immunoliposome-Conjugated Antibodies at PEG Terminals (Abstract Only-Applicants do not have comple copy), Publ: Advanced Drug Delivery Reviews, vol./Iss: 24, pp. 235-242, Date: Mar. 17, 1997.53Author: Mathias et al., Title: Sulfur-Substituted Polyoxyethylenes Sequential Ether-Thioether Copolymers, Publ: Crown Ethers and Phase Transfer Catalysis in Polymer Science, vol./Iss:, pp. 359-370, Date: Jan. 1, 1984.54Author: Morris et al., Title: Validation of the Biotinyl Ligant-Avidin-Gold Technique, Publ: Cyctochemistry, vol./Iss: 40, pp. 711-721, Date: Jan. 1, 1992.55Author: Mrksich et al., Title: Surface Plasmon Resonance Permits in Situ Measurement of Protein Adsorption on Self-Assembled Monolayers of Alkanethiolates on Gold, Publ: Langmuir, vol./Iss: 11, pp. 4383-4385, Date: Jan. 1, 1995.56Author: Nakashima et al., Title: Electrochemical Characterization of an Assembled Monolayers of alpha-Methoxy-omegamercapto-poly(ethylene glycol) on Gold and Complex Formation of the Monolayer with alpha-Cyclodextrin, Publ: Chemistry Letters, vol./Iss:, pp. 731-732, Date: Jan. 1, 1996.57Author: Nakashima et al., Title: Electrochemical Characterization of an Assembled Monolayers of α-Methoxy-ωmercapto-poly(ethylene glycol) on Gold and Complex Formation of the Monolayer with α-Cyclodextrin, Publ: Chemistry Letters, vol./Iss:, pp. 731-732, Date: Jan. 1, 1996.58Author: Niwa et al., Title: Two-Dimensional Array of Poly(methacrylic acid) Brushes on Gold Substrates. Interaction with Ferrocen-Terminated Poly(oxyethylene)s, Publ: Macromolecules, vol./Iss: 28(23), pp. 7770-7774, Date: Nov. 6, 1995.59Author: Ormann et al., Title: Expression of Tumor Necrosis Factor-alpha Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Luekocytes Internalization of Receptor-Bound Ligand, and Some Functional Effects, Publ: Lymphokine Research, vol./Iss: 9(1), pp. 43-58, Date: Jan. 1, 1990.60Author: Ormann et al., Title: Expression of Tumor Necrosis Factor-α Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Luekocytes Internalization of Receptor-Bound Ligand, and Some Functional Effects, Publ: Lymphokine Research, vol./Iss: 9(1), pp. 43-58, Date: Jan. 1, 1990.61Author: Otsuka et el., Title: Quantitative and Reversible Lectin-Induced Association of Gold Nanoparticles Modified with alpha-Lactosyl-omega-mercapto-poly(ethylene glycol), Publ: Journal of the American Chemical Society, vol./Iss: 123, pp. 8226-8230, Date: Feb. 20, 2001..62Author: Otsuka et el., Title: Quantitative and Reversible Lectin-Induced Association of Gold Nanoparticles Modified with α-Lactosyl-ω-mercapto-poly(ethylene glycol), Publ: Journal of the American Chemical Society, vol./Iss: 123, pp. 8226-8230, Date: Feb. 20, 2001..63Author: Paciotti et al., Title: (XP-001537146) #3858-Comparison of the Toxicity and Pharmacokinetics of Neat and Colloidal Gold Bound TNF, Publ: Proceedings of the American Association for Cancer Research, vol./Iss: 40, pp. 585, Date: Mar. 1, 1999.64Author: Paciotti et al., Title: (XP-001537146) #3858�Comparison of the Toxicity and Pharmacokinetics of Neat and Colloidal Gold Bound TNF, Publ: Proceedings of the American Association for Cancer Research, vol./Iss: 40, pp. 585, Date: Mar. 1, 1999.65Author: Paciotti et al., Title: (XP-001537149) #1048-The Use of Colloidal Gold in Cytokine Immunotherapy, Publ: Proceedings of the American Association for Cancer Research, vol./Iss: 39, pp. 153, Date: Mar. 1, 1998.66Author: Paciotti et al., Title: (XP-001537149) #1048�The Use of Colloidal Gold in Cytokine Immunotherapy, Publ: Proceedings of the American Association for Cancer Research, vol./Iss: 39, pp. 153, Date: Mar. 1, 1998.67Author: Paciotti et al., Title: Interleukin 1 Directly Regulates Hormone-Dependent Human Breast Cancer Cell Proliferation in Vivo, Publ: Molecular Endocrinology, vol./Iss: 2, pp. 459-464, Date: Jan. 1, 1988.68Author: Paciotti et al., Title: Interleukin 1alpha Differentially Synchronizes Estrogen Dependent and Estrogen-Independent Human Breast Cells in G0/G1 Phase of the Cell Cycle, Publ: Anti-Cancer Research, vol./Iss: 11, pp. 25-32, Date: Jan. 1, 1991.69Author: Paciotti et al., Title: Interleukin 1α Differentially Synchronizes Estrogen Dependent and Estrogen-Independent Human Breast Cells in G0/G1 Phase of the Cell Cycle, Publ: Anti-Cancer Research, vol./Iss: 11, pp. 25-32, Date: Jan. 1, 1991.70Author: Paciotti et al., Title: Interleukin 2 Differentially Effects the Proliferation of a Hormone-Dependent and a Hormone-Independent Human Breast Cancer Cell Line in Vitro and in Vivo, Publ: Anti-Cancer Research, vol./Iss: 8, pp. 1233-1249, Date: Jan. 1, 1988.71Author: Peters et al., Title: Binding and Internalization of Biotinylated Interleukin-2 in Human Lymphocytes, Publ: Blood, vol./Iss: 76, pp. 97-104, Date: Jan. 1, 1990.72Author: Prakken et al., Title: Artificial Antigen-Presenting Cells as a Tool to Exploit the Immune �Synapse�, Publ: Nature Medicine, vol./Iss: 6(12), pp. 1406-1410, Date: Dec. 1, 2000.73Author: Prakken et al., Title: Artificial Antigen-Presenting Cells as a Tool to Exploit the Immune 'Synapse', Publ: Nature Medicine, vol./Iss: 6(12), pp. 1406-1410, Date: Dec. 1, 2000.74Author: Prime et al., Title: Adsorption of Proteins onto Surfaces Containing End-Attached Oligo(ethylene oxide): A Model System Using Self-Assembled Monolayers, Publ: Journal of the American Chemical Society, vol./Iss: 115, pp. 10714-10721, Date: Jan. 1, 1993.75Author: Rabolt, J.F., Title: Design and Construction of Two Component Heterogenous Polymer Surfaces by Self Assembly, Publ: Polymer Preprints, vol./Iss: 36(1), pp. 84, Date: Apr. 1, 1995.76Author: Roitt et al., Title: The Cytokine Network, Publ: Immunology, vol./Iss: 3rd Ed., pp. 8-15, Date: Jan. 1, 1993.77Author: Ross et al., Title: Gene Therapy in the United States: A Five-Year Status Report, Publ: Human Gene Therapy, vol./Iss: 7, pp. 1781-1790, Date: Sep. 10, 1996.78Author: Rubanyi, G.M., Title: The Future of Human Gene Therapy, Publ: Molecular Aspects of Medicine, vol./Iss: 22, pp. 113-142, Date: Jan. 1, 2001.79Author: Schmitmeier et al., Title: Anti-Invasive Effect of Contortrostatin. A snake Venom Disintegrin, and TNF-alpha on Malignant Glioma Cells-(Applicants do not have complete copy), Publ: Anti-Cancer Research, vol./Iss: 20(6B), pp. 4227-4233, Date: Nov. 1, 2000.80Author: Tannock et al., Title:, Publ: The Basic Science of Oncology, vol./Iss: 2nd Ed., pp. 352-353, Date: Jan. 1, 1992.81Author: Tomii et al., Title: Production of Anti-Platelet-Activating Factor Antibodies by the Use of Colloidal Gold as Cancer, Publ: Japane Journal of Medicinal Science and Biology, vol./Iss: 44, pp. 75-80, Date: Jan. 1, 1991.82Author: USPTO, Title: USPTO Office Action-cited 11/516,175, Publ: USPTO Office Action, vol./Iss:, pp. 1-9, Date: Jun. 5, 2009.83Author: USPTO, Title: USPTO Office Action�cited 11/516,175, Publ: USPTO Office Action, vol./Iss:, pp. 1-9, Date: Jun. 5, 2009.84Author: USPTO, Title: USPTO Office Action-cited in 11/516,175, Publ: USPTO Office Action, vol./Iss:, pp. 1-10, Date: Sep. 11, 2009.85Author: USPTO, Title: USPTO Office Action�cited in 11/516,175, Publ: USPTO Office Action, vol./Iss:, pp. 1-10, Date: Sep. 11, 2009.86Author: USPTO, Title: USPTO Office Action-cited in 11/805,383, Publ: USPTO Office Action, vol./Iss:, pp. 1-16, Date: Apr. 17, 2009.87Author: USPTO, Title: USPTO Office Action�cited in 11/805,383, Publ: USPTO Office Action, vol./Iss:, pp. 1-16, Date: Apr. 17, 2009.88Author: USPTO, Title: USPTO Office Action-cited in 11/805,383, Publ: USPTO Office Action, vol./Iss:, pp. 1-33, Date: Aug. 19, 2009.89Author: USPTO, Title: USPTO Office Action�cited in 11/805,383, Publ: USPTO Office Action, vol./Iss:, pp. 1-33, Date: Aug. 19, 2009.90Author: Van Den Pol, A. N., Title: Colloidal Gold and Biotin-Avidin Conjugates as Ultrasound Markers for Neural Antigens, Publ: Quarterly Journal of Experimental Physiology, vol./Iss:, pp. 1-33, Date: Jan. 1, 1984.91Author: Van Rensen et al., Title: Liposomes with Incorporated MHC Class II/Peptide Complexes as Antigen Presenting Vesicles for Specific T Cell Activation, Publ: Pharmaceutical Research, vol./Iss: 16(2), pp. 198-204, Date: Jan. 1, 1999.92Author: Verma et al., Title: Gene Therapy-Promises, Problems and Prospects, Publ: Nature, vol./Iss: 389, pp. 239-242, Date: Sep. 18, 1997.93Author: Verma et al., Title: Gene Therapy�Promises, Problems and Prospects, Publ: Nature, vol./Iss: 389, pp. 239-242, Date: Sep. 18, 1997.94Author: Vidal et al., Title: Steric Stabilization of Polystyrene Colloids Using Thiol-ended Polyethylene Oxide, Publ: Polymers for Advanced Technologies, vol./Iss: 6, pp. 473-479, Date: Nov. 15, 1994.95Author: Walden et al., Title: Induction of Regulatory T-lymphocyte Responses by Liposomes Carrying Major Histocompatibility Complex Molecules and Foreing Antigen, Publ: Nature, vol./Iss: 315, pp. 327-329, Date: May 23, 1985.96Author: Wink et al., Title: Interation Between Plasmid DNA and Cationic Polymers Studied by Surface Plasmon Resonance Spectrometry Publ: Analytical Chemistry, vol./Iss: 71, pp. 801-805, Date: Jan. 1, 1999.97Author: Wuelling et al., Title: Nanometer Gold Clusters Protected by Surface-Bound Monolayers of Thiolated Poly (ethylene glycol) Polymer Electrolyte, Publ: Journal of the American Chemical Society, vol./Iss: 120, pp. 12696-12697, Date: Jan. 1, 1998.98Author:, Title: "Cancer", Publ: Taber's Cyclopedic Medical Disctionary, vol./Iss: Ed. 16, pp. 274, Date: Jan. 1, 1985.99Author:, Title: Appicants do not have translation; Concise Statement: This reference describes the use of acetal-PEG-dimethyllaminotheylpolymethacrylate as a dispersion stabilizer for fine particles of gold, Publ: Polymer Preprints, vol./Iss: 49(3), pp. 650, Date: Jan. 1, 2000.100Author:, Title: Australian Office Action-Application No. 2002259107, Publ: Australian Office Action, vol./Iss:, pp. 1-2, Date: Nov. 14, 2005.101Author:, Title: Australian Office Action�Application No. 2002259107, Publ: Australian Office Action, vol./Iss:, pp. 1-2, Date: Nov. 14, 2005.102Author:, Title: Canadian Office Action-2,309,604, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: Feb. 11, 2006.103Author:, Title: Canadian Office Action�2,309,604, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: Feb. 11, 2006.104Author:, Title: Canadian Office Action-2,309,604, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: May 18, 2006.105Author:, Title: Canadian Office Action�2,309,604, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: May 18, 2006.106Author:, Title: Canadian Office Action-Application No. 2,448,607, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: Apr. 7, 2009.107Author:, Title: Canadian Office Action�Application No. 2,448,607, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: Apr. 7, 2009.108Author:, Title: EPO Office Action cited in 02729092.3 (CYT0091EP), Publ: EPO Office Action, vol./Iss:, pp. 1-4, Date: Oct. 23, 2009.109Author:, Title: EPO Search Report cited in EP Application No. 05722719.9 (CYT-0094EP) Publ: EPO Search Report, vol./Iss:, pp. 1-4, Date: Sep. 15, 2010.110Author:, Title: EPO Search Report-98957757.2, Publ: EPO Search Report, vol./Iss:, pp. 1-3, Date: Oct. 31, 2003.111Author:, Title: EPO Search Report�98957757.2, Publ: EPO Search Report, vol./Iss:, pp. 1-3, Date: Oct. 31, 2003.112Author:, Title: EPO Search Report-98957757.2, Publ: EPO Search Report, vol./Iss:, pp. 1-4, Date: Oct. 31, 2003.113Author:, Title: EPO Search Report�98957757.2, Publ: EPO Search Report, vol./Iss:, pp. 1-4, Date: Oct. 31, 2003.114Author:, Title: Japanese Office Action cited in 2000-520162 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-3, Date: Jun. 4, 2010.115Author:, Title: Japanese Office Action cited in 2000-520162 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-3, Date: Oct. 22, 2009.116Author:, Title: Japanese Office Action cited in 2000-520162 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-7, Date: Apr. 14, 2009.117Author:, Title: Japanese Office Action cited in 2002-584861 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-10, Date: Dec. 25, 2008.118Author:, Title: Japanese Office Action cited in 2006-551620 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-4, Date: Jul. 13, 2010.119Author:, Title: Office Action-Peoples Republic of China-Application No. 200580009719.0 (with English translation) Publ: Peoples Republic of China-Office Action, vol./Iss:, pp. 1-15, Date: Mar. 20, 2009.120Author:, Title: Office Action�Peoples Republic of China�Application No. 200580009719.0 (with English translation) Publ: Peoples Republic of China�Office Action, vol./Iss:, pp. 1-15, Date: Mar. 20, 2009.121Author:, Title: PCT International Search Report and Written Opinion issued in PCT/US08/77239 (CYT-0166) Publ: PCT International Search Report, vol./Iss:, pp. 107, Date: Dec. 5, 2008.122Author:, Title: USPTO Office Action-cited in 09/189,657, Publ: USPTO Office Action, vol./Iss:, pp. 1-15, Date: Apr. 11, 2008.123Author:, Title: USPTO Office Action�cited in 09/189,657, Publ: USPTO Office Action, vol./Iss:, pp. 1-15, Date: Apr. 11, 2008.124Author:, Title: USPTO Office Action-cited in 10/672,144 (CYT-0027), Publ: USPTO Office Action, vol./Iss:, pp. 1-5, Date: Nov. 15, 2010.125Author:, Title: USPTO Office Action�cited in 10/672,144 (CYT-0027), Publ: USPTO Office Action, vol./Iss:, pp. 1-5, Date: Nov. 15, 2010.126Author:, Title: USPTO Office Action-cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-10, Date: Apr. 15, 2009.127Author:, Title: USPTO Office Action�cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-10, Date: Apr. 15, 2009.128Author:, Title: USPTO Office Action-cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-6, Date: Aug. 5, 2010.129Author:, Title: USPTO Office Action�cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-6, Date: Aug. 5, 2010.130Author:, Title: USPTO Office Action-cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-8, Date: Jan. 20, 2010.131Author:, Title: USPTO Office Action�cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-8, Date: Jan. 20, 2010.132Author:, Title: USPTO Office Action-cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-8, Date: Oct. 17, 2007.133Author:, Title: USPTO Office Action�cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-8, Date: Oct. 17, 2007.134Author:, Title: USPTO Office Action�cited in 11/016,204, Publ: USPTO Office Action, vol./Iss:, pp. 1-36, Date: Jul. 7, 2009.135Author:, Title: USPTO Office Action-cited in 12/250,126, Publ: USPTO Office Action, vol./Iss:, pp. 1-12, Date: Jun. 7, 2010.136Author:, Title: USPTO Office Action�cited in 12/250,126, Publ: USPTO Office Action, vol./Iss:, pp. 1-12, Date: Jun. 7, 2010.137Author:, Title: USPTO Office Action�cited in 12/708,326 (CYT-0110), Publ: USPTO Office Action, vol./Iss:, pp. 1-15, Date: Nov. 8, 2010.138Office Action in U.S. Appl. No. 11/046,204, filed Oct. 16, 2008. Citada por Patente citante Fecha de presentaci�n Fecha de publicaci�n Solicitante T�tuloUS20120134956 *26 Oct 201131 May 2012Cytimmune Sciences, Inc.Colloidal metal compositions and methods* Citada por examinadorClasificaciones Clasificaci�n de EE.UU.436/525, 436/518 Clasificaci�n internacionalG01N33/553, C07K14/525, C07K16/24, A61K47/48, A61K9/00, A61K39/39 Clasificaci�n cooperativaA61K49/0056, A61K2039/55505, C07K14/525, A61K2039/55516, A61K49/0017, A61K51/1244, C07K16/241, A61K38/191, A61K49/0013, A61K49/0065, A61K39/39, A61K47/48861, A61K47/48215, A61K2039/55522, A61K38/39 Clasificaci�n europeaC07K14/525, A61K49/00P4, C07K16/24B, A61K49/00P4F8R, A61K39/39, A61K49/00P12, A61K38/39, A61K51/12H, A61K38/19A, A61K49/00P4F, A61K47/48K6P, A61K47/48W8BGirarImagen originalP�gina principal de Google - Sitemap - Descargas masivas de USPTO - Pol�tica de privacidad - Condiciones de servicio - Acerca de Google Patentes - Danos tu opini�nDatos proporcionados por IFI CLAIMS Patent Services©2012 Google